Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLRNASDAQ:GLMDNASDAQ:NRBONASDAQ:PHIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$0.93+6.7%$0.97$0.61▼$10.59$14.02M-0.151.13 million shs813,516 shsGLMDGalmed Pharmaceuticals$1.87+5.1%$1.45$1.15▼$23.80$3.09M0.511.32 million shs934,112 shsNRBONeuroBo Pharmaceuticals$0.68-3.4%$0.77$2.08▼$5.30$5.83M-0.2651,808 shs51,705 shsPHIOPhio Pharmaceuticals$2.27-3.8%$2.15$0.97▼$9.79$10.87M0.842.45 million shs171,606 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics0.00%+15.77%-12.68%-6.06%-92.98%GLMDGalmed Pharmaceuticals0.00%+16.88%+32.62%-17.26%-53.54%NRBONeuroBo Pharmaceuticals-3.41%-7.65%-2.09%-56.38%-82.39%PHIOPhio Pharmaceuticals0.00%0.00%+23.37%+75.97%-64.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AGLMDGalmed Pharmaceuticals0.336 of 5 stars0.02.00.00.00.02.50.6NRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/APHIOPhio Pharmaceuticals3.0828 of 5 stars3.55.00.00.01.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 0.00N/AN/AN/AGLMDGalmed Pharmaceuticals 2.00HoldN/AN/ANRBONeuroBo Pharmaceuticals 0.00N/AN/AN/APHIOPhio Pharmaceuticals 3.00Buy$14.00516.74% UpsideCurrent Analyst Ratings BreakdownLatest NRBO, ALLR, GLMD, and PHIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.004/8/2025PHIOPhio PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/4/2025GLMDGalmed PharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/A$9.87 per shareN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/A$1.50 per shareN/APHIOPhio PharmaceuticalsN/AN/AN/AN/A$0.69 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)GLMDGalmed Pharmaceuticals-$7.52M-$16.66N/A∞N/AN/A-32.21%-28.59%8/26/2025 (Estimated)NRBONeuroBo Pharmaceuticals-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%8/12/2025 (Estimated)PHIOPhio Pharmaceuticals-$7.15M-$10.92N/A0.60N/AN/A-105.65%-89.19%8/13/2025 (Estimated)Latest NRBO, ALLR, GLMD, and PHIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025GLMDGalmed PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/AGLMDGalmed PharmaceuticalsN/AN/AN/AN/AN/ANRBONeuroBo PharmaceuticalsN/AN/AN/AN/AN/APHIOPhio PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.662.66GLMDGalmed PharmaceuticalsN/A9.029.02NRBONeuroBo PharmaceuticalsN/A2.412.41PHIOPhio PharmaceuticalsN/A10.5810.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%GLMDGalmed Pharmaceuticals76.14%NRBONeuroBo Pharmaceuticals1.37%PHIOPhio Pharmaceuticals57.31%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%GLMDGalmed Pharmaceuticals19.80%NRBONeuroBo Pharmaceuticals1.05%PHIOPhio Pharmaceuticals0.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.08 million15.07 millionNot OptionableGLMDGalmed Pharmaceuticals201.65 million1.33 millionNot OptionableNRBONeuroBo Pharmaceuticals108.62 million8.53 millionNot OptionablePHIOPhio Pharmaceuticals104.80 million4.77 millionNot OptionableNRBO, ALLR, GLMD, and PHIO HeadlinesRecent News About These CompaniesPhio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA PortfolioJune 6, 2025 | newsfilecorp.comBest Value Stocks to Buy for May 28thMay 28, 2025 | zacks.comNew Strong Buy Stocks for May 28thMay 28, 2025 | zacks.comPhio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor ConferenceMay 19, 2025 | newsfilecorp.comPhio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | newsfilecorp.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialMay 7, 2025 | finanznachrichten.dePhio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical TrialMay 7, 2025 | newsfilecorp.comPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesMay 1, 2025 | newsfilecorp.comBest Momentum Stocks to Buy for April 23rdApril 23, 2025 | zacks.comBest Value Stocks to Buy for April 23rdApril 23, 2025 | zacks.comPhio Pharmaceuticals Corp. Common StockApril 12, 2025 | fxempire.comPhio Pharmaceuticals announces Safety Monitoring Committee recommendation to advance INTASYL PH-762 skin cancer studyApril 12, 2025 | pharmabiz.comPhio advances skin cancer treatment with successful trialApril 11, 2025 | uk.investing.comPHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next DoseApril 10, 2025 | zacks.comThis Biotech Is Ripping Following Phase 1b Trial AnnouncementApril 9, 2025 | msn.comPhio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s ThrilledApril 9, 2025 | msn.comPhio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation CohortApril 9, 2025 | newsfilecorp.comAnalysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Phio Pharmaceuticals (PHIO)April 8, 2025 | markets.businessinsider.comPhio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894April 3, 2025 | newsfilecorp.comPhio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business UpdateMarch 31, 2025 | newsfilecorp.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRBO, ALLR, GLMD, and PHIO Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$0.93 +0.06 (+6.71%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.94 +0.01 (+1.08%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Galmed Pharmaceuticals NASDAQ:GLMD$1.87 +0.09 (+5.06%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.88 +0.00 (+0.27%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.NeuroBo Pharmaceuticals NASDAQ:NRBO$0.68 -0.02 (-3.41%) As of 06/20/2025NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.Phio Pharmaceuticals NASDAQ:PHIO$2.27 -0.09 (-3.81%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.23 -0.04 (-1.76%) As of 06/20/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
